WO2003000227A3 - A method for preparation of vesicles loaded with biological material and different uses thereof - Google Patents

A method for preparation of vesicles loaded with biological material and different uses thereof Download PDF

Info

Publication number
WO2003000227A3
WO2003000227A3 PCT/IL2002/000506 IL0200506W WO03000227A3 WO 2003000227 A3 WO2003000227 A3 WO 2003000227A3 IL 0200506 W IL0200506 W IL 0200506W WO 03000227 A3 WO03000227 A3 WO 03000227A3
Authority
WO
WIPO (PCT)
Prior art keywords
biological material
preparation
different uses
vesicles loaded
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2002/000506
Other languages
French (fr)
Other versions
WO2003000227A2 (en
Inventor
Yechezkel Barenholz
Eliezer Kedar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Priority to US10/482,112 priority Critical patent/US20060029655A1/en
Priority to CA002451091A priority patent/CA2451091A1/en
Priority to EP02738605A priority patent/EP1404298A2/en
Priority to AU2002311616A priority patent/AU2002311616B2/en
Priority to IL15933402A priority patent/IL159334A0/en
Priority to JP2003506874A priority patent/JP2005525992A/en
Publication of WO2003000227A2 publication Critical patent/WO2003000227A2/en
Publication of WO2003000227A3 publication Critical patent/WO2003000227A3/en
Priority to IL159334A priority patent/IL159334A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

The present invention discloses a method for an efficient entrapment of active biological material in liposomes. The method is based on the steps of drying a suspension of liposome-forming lipids and then hydrating the dry composition obtained with an aqueous solution containing a biologically active material to be entrapped in high yield in the liposomes thus formed. The invention also concerns liposomal formulations produced by the method of the invention and their uses.
PCT/IL2002/000506 2001-06-25 2002-06-25 A method for preparation of vesicles loaded with biological material and different uses thereof Ceased WO2003000227A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/482,112 US20060029655A1 (en) 2001-06-25 2002-06-25 Method for preparation of vesicles loaded with biological material and different uses thereof
CA002451091A CA2451091A1 (en) 2001-06-25 2002-06-25 A method for preparation of vesicles loaded with biological material and different uses thereof
EP02738605A EP1404298A2 (en) 2001-06-25 2002-06-25 A method for preparation of vesicles loaded with biological material and different uses thereof
AU2002311616A AU2002311616B2 (en) 2001-06-25 2002-06-25 A method for preparation of vesicles loaded with biological material and different uses thereof
IL15933402A IL159334A0 (en) 2001-06-25 2002-06-25 A method for preparation of vesicles loaded with biological material and different uses thereof
JP2003506874A JP2005525992A (en) 2001-06-25 2002-06-25 Methods for the preparation of vesicles filled with biological material and their various uses
IL159334A IL159334A (en) 2001-06-25 2003-12-11 Method for preparing vesicles loaded with biological material, their uses and a combination of pharmaceutical compositions for preparing such vesicles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30006501P 2001-06-25 2001-06-25
US60/300,065 2001-06-25

Publications (2)

Publication Number Publication Date
WO2003000227A2 WO2003000227A2 (en) 2003-01-03
WO2003000227A3 true WO2003000227A3 (en) 2003-11-13

Family

ID=23157552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000506 Ceased WO2003000227A2 (en) 2001-06-25 2002-06-25 A method for preparation of vesicles loaded with biological material and different uses thereof

Country Status (7)

Country Link
US (1) US20060029655A1 (en)
EP (1) EP1404298A2 (en)
JP (1) JP2005525992A (en)
AU (1) AU2002311616B2 (en)
CA (1) CA2451091A1 (en)
IL (1) IL159334A0 (en)
WO (1) WO2003000227A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
KR20060015534A (en) 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 Methods and systems for growth inhibition, systemic delivery of lipid-derived bioactive compounds
DK1765289T3 (en) * 2004-07-07 2008-12-15 Statens Seruminstitut Compositions and Methods for Stabilizing Lipid-Based Adjuvant Formulations Using Glycolipids
EP1676569A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
CN101365424A (en) * 2005-12-08 2009-02-11 耶路撒冷希伯来大学伊森姆研究发展公司 Method for changing the composition of liposomes by ultrasonic irradiation
JP5660561B2 (en) * 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド Use of glycerophospholipids for joint lubrication
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2010033863A2 (en) * 2008-09-18 2010-03-25 Juvaris Biotherapeutics, Inc. Vaccine compositions of m2e, ha0 and bm2 multiple antigenic peptides
US20110250266A1 (en) * 2008-10-07 2011-10-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomal systems comprising sphingomyelin
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US20130039973A1 (en) * 2011-08-03 2013-02-14 Henry J. Smith Viral Immunogenic Compositions
WO2013113325A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP3838294A1 (en) * 2012-01-31 2021-06-23 CureVac AG Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2014116866A1 (en) * 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
BR112016003361A2 (en) 2013-08-21 2017-11-21 Curevac Ag respiratory syncytial virus vaccine (rsv)
US10639278B2 (en) * 2013-10-22 2020-05-05 Lipella Pharmaceuticals, Inc. Delivery of agents using metastable liposomes
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015168393A1 (en) * 2014-04-30 2015-11-05 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10722599B2 (en) 2015-02-04 2020-07-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies
CN121154578A (en) * 2017-04-21 2025-12-19 科斯塔治疗公司 Membrane lipid coated nanoparticles and methods of use thereof
FI3672653T3 (en) * 2017-08-22 2023-06-07 Moebius Medical Ltd LIPOSOM FORMULATION FOR JOINT LUBRICATION
CN111902397B (en) 2018-03-27 2024-04-12 日油株式会社 Cationic lipids with improved intracellular kinetics
KR20210149157A (en) 2019-05-14 2021-12-08 파모사 바이오팜 인코포레이티드 Pharmaceutical composition and administration method of weakly acidic drug
WO2021060440A1 (en) * 2019-09-26 2021-04-01 日油株式会社 Lipid nanoparticle lyophilized composition
CA3266614A1 (en) 2023-01-19 2024-07-25 Moebius Medical Ltd. A long-acting liposomal composition for treatment of pain in articular disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004412A1 (en) * 1988-10-27 1990-05-03 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
WO1997029769A1 (en) * 1996-02-16 1997-08-21 Biomira Usa Inc. Vaccine for b-cell malignancies
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
WO2000061766A2 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4898735A (en) * 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US5043166A (en) * 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
ATE210966T1 (en) * 1993-05-21 2002-01-15 Liposome Co Inc REDUCING PHYSIOLOGICAL COUNTERREACTIONS INDUCED BY LIPOSOMES
DE69935507T2 (en) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM BY IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINES
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
KR20050025306A (en) * 2002-07-03 2005-03-14 애프톤 코포레이션 Liposomal vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004412A1 (en) * 1988-10-27 1990-05-03 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
WO1997029769A1 (en) * 1996-02-16 1997-08-21 Biomira Usa Inc. Vaccine for b-cell malignancies
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
WO2000061766A2 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABAI I., ET AL.: "A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice", VACCINE, vol. 17, no. 9-10, 5 March 1999 (1999-03-05), pages 1223 - 1238, XP002225447 *
CABANES A., ET AL.: "Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2", CLINICAL CANCER RESEARCH, vol. 5, no. 3, March 1999 (1999-03-01), pages 687 - 693, XP002225446 *

Also Published As

Publication number Publication date
IL159334A0 (en) 2004-06-01
CA2451091A1 (en) 2003-01-03
JP2005525992A (en) 2005-09-02
WO2003000227A2 (en) 2003-01-03
US20060029655A1 (en) 2006-02-09
AU2002311616B2 (en) 2007-11-22
EP1404298A2 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
WO2003000227A3 (en) A method for preparation of vesicles loaded with biological material and different uses thereof
Shew et al. A novel method for encapsulation of macromolecules in liposomes
FI119621B (en) Preparation of Multivesicular Liposomes for Controlled Release of Active Agents
US5128139A (en) Composition containing liposome-entrapped grapefruit seed extract and method for making
CA2250219A1 (en) Materials and methods for making improved liposome compositions
AU1491788A (en) Liposome-incorporated nystatin
ATE203898T1 (en) METHOD FOR PRODUCING A LIPOSOME PREPARATION
CA2289702A1 (en) High efficiency encapsulation of charged therapeutic agents in lipid vesicles
CA2108288A1 (en) Liposomal cyclosporin formulation and process for the preparation thereof
CA2246456A1 (en) Lipids and their use, for example, in liposomes
EP1764091A3 (en) Improvements in or relating to amphoteric liposomes
JP2003513003A5 (en)
KR101474577B1 (en) Cardiolipin-containing liposome for improving mitochondrial function
IE830318L (en) Lipids in aqueous phase
IE811298L (en) Magnetically-localizable biodegradable lipid microspheres
WO2002043699A3 (en) Preparation of large liposomes by infusion into peg
CA2213151A1 (en) Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
WO1999016426A3 (en) Multilamellar coalescence vesicles (mlcv) containing biologically active compounds
CA2117769A1 (en) Liposome composition
AU7538587A (en) Method of preparing single bilayered liposomes
DE59510668D1 (en) UNILAMELLAR LIPOSOME PREPARATIONS WITH HIGH ACTIVE SUBSTANCE
ES2086802T3 (en) LIPOSOMIC FORMULATIONS OF ACTIVE PRINCIPLES AND PROCEDURE FOR THE PREPARATION.
JPS5782311A (en) Production of liposome preparation
Crommelin et al. Liposomes as carriers for drugs and antigens: approaches to preserve their long term stability
AU2002233822A1 (en) Oral itraconazole formulations and methods of making the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159334

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002311616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2451091

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003506874

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002738605

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002738605

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2006029655

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10482112

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10482112

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2002311616

Country of ref document: AU

Date of ref document: 20020625

Kind code of ref document: B